Glucose-lowering medications and post-dementia survival in patients with diabetes and dementia

Manuscript Number: 

21-5337R1

Author(s): 
Michael Alvarsson, Maria Eriksdotter, Sara Garcia-Ptacek, Niklas Hammar, Dorota Religa, Emilia Schwertner, Juraj Secnik, Bengt Winblad, Hong Xu

Disclosures

Michael Alvarsson

  • Lecture Fees:
    I have received lecture fees from Novo Nordisk, Eli Lilly and AstraZeneca.

Maria Eriksdotter

  • Lecture Fees:
    Honoraria for Speaker on Covid-19 and Aging at Symposia April 22, 2021 organized by Journal of the Swedish Medical Association Honoraria for Speaker on Dementia at Educational event organized by Gothia Fortbildning Feb 6 2020 Honoraria for lecture on dementia in symposia Oct 24 2019, organized by Journal of the Swedish Medical Association

Sara Garcia-Ptacek

  • Equity:
    AstraZeneca, Pfizer, Moderna, Camurus as pension savings

Niklas Hammar

  • Consulting Fees:
    Senior Advisor Swedish Orphan Biovitrum consulting fee
    Equity:
    AstraZeneca shares

Dorota Religa

  • Nothing to Disclose

Emilia Schwertner

  • Nothing to Disclose

Juraj Secnik

  • Nothing to Disclose

Bengt Winblad

  • Consulting Fees:
    I am paid for SAB for: Alzinova, Alzecure, Axon Neuroscience, Biogen.

Hong Xu

  • Nothing to Disclose